The estimated Net Worth of Lance Baldo is at least $3.85 Milione dollars as of 8 March 2022. Lance Baldo owns over 3,350 units of Adaptive Biotechnologies stock worth over $75,381 and over the last 5 years he sold ADPT stock worth over $66,790. In addition, he makes $3,707,390 as Chief Medical Officer at Adaptive Biotechnologies.
Lance has made over 15 trades of the Adaptive Biotechnologies stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 3,350 units of ADPT stock worth $38,291 on 8 March 2022.
The largest trade he's ever made was exercising 50,000 units of Adaptive Biotechnologies stock on 6 May 2020 worth over $390,000. On average, Lance trades about 12,734 units every 39 days since 2020. As of 8 March 2022 he still owns at least 17,171 units of Adaptive Biotechnologies stock.
You can see the complete history of Lance Baldo stock trades at the bottom of the page.
Dr. Lance Baldo MD. serves as Chief Medical Officer of the Company. From March 2010 to April 2019, Dr. Baldo served in various roles of ascending responsibility with the Roche Group, a global healthcare company, and its affiliates, including most recently as Senior Vice President and Head of U.S. Medical Affairs of Genentech. Prior to joining the Roche Group, Dr. Baldo served as Global Vice President, Medical Science and Affairs at The Medicines Company, a public biopharmaceuticals company, from October 2004 to February 2010. Dr. Baldo holds an MD from the University of Connecticut School of Medicine and a BA in Biology from John Hopkins University.
As the Chief Medical Officer of Adaptive Biotechnologies, the total compensation of Lance Baldo at Adaptive Biotechnologies is $3,707,390. There are no executives at Adaptive Biotechnologies getting paid more.
Lance Baldo is 47, he's been the Chief Medical Officer of Adaptive Biotechnologies since 2019. There are 16 older and 7 younger executives at Adaptive Biotechnologies. The oldest executive at Adaptive Biotechnologies Corporation is Peter Neupert, 64, who is the Lead Independent Director.
Lance's mailing address filed with the SEC is 1165 EASTLAKE AVENUE E, , SEATTLE, WA, 98109.
Over the last 5 years, insiders at Adaptive Biotechnologies have traded over $685,617,014 worth of Adaptive Biotechnologies stock. The most active insiders traders include Global Investors Lp Viking ..., Global Performance Llc Viki... e Kevin T Conroy. On average, Adaptive Biotechnologies executives and independent directors trade stock every 6 days with the average trade being worth of $368,167. The most recent stock trade was executed by Stacy L Taylor on 22 August 2024, trading 26,922 units of ADPT stock currently worth $121,149.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies executives and other stock owners filed with the SEC include: